Phase 2 N=52 Nivolumab Plus Ipilimumab in Thyroid Cancer
Thyroid Cancer
Primary: Best Overall Response Rate — 9.4; 0; 30 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=111 Assess Vitamin D Levels in Those With & Without Thyroid Cancer
Thyroid Cancer
Primary: Number of Persons That Are Vitamin D Deficient in the Thyroid Nodule, Thyroid Cancer in Remission, and the Active Thyroid Cancer Groups. — 23; 20; 11 participants…
Phase 2 N=60 Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 38.3 Percentage of participants
Phase 2 N=63 Recombinant Thyrotropin PET-CT Fusion Scanning in Thyroid Cancer
Thyroid Cancer
Primary: PET-CT Fusion Scanning Sensitivity — 49; 54 percentage of participants
Phase 2 N=27 Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer
Thyroid Cancer
Primary: Percentage of Participants With Local-regional Progression-free Survival — 15.2 percentage of all participants
Phase 2 N=23 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer
Papillary Thyroid Cancer · Follicular Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Progression Free Survival — 241 days
Phase 2 N=1 Pioglitazone in Thyroid Cancers
Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene
Primary: Tumor Response (Change) — 6.0; 3.9 cm
N/A N=12 Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study
Papillary Carcinoma of Thyroid Gland · Metastatic Medullary Thyroid Cancer · Follicular Thyroid Cancer Lymph Node Metastasis
Primary: Primary Efficacy Parameters of Sensitivity of High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles (LSN MRI) — 85.5 percentage…
Phase 2 N=90 Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer
Stage I Papillary Thyroid Cancer · Stage II Papillary Thyroid Cancer · Stage III Papillary Thyroid Cancer
Primary: Percentage of Participants With Transient Hypoparathyroidism, as Defined by a Day 1 Serum Parathyroid Hormone (PTH) Level of < 10 pg/ml — 24.1; 33.3 percentage of…
Early Phase 1 N=10 A Pilot Clinical Trial for Poorly Differentiated Thyroid Cancer - Correlation to Retinoid and Peroxisome-proliferator-activated Receptor (PPARy) Expression
Thyroid Cancer
Primary: Change in Tumor Size — 4.7 cm
Phase 2 N=6 Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Anaplastic Thyroid Cancer
Primary: Overall Response (OR) — 0; 3; 3; 1 Participants
Phase 2 N=63 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Refractory Thyroid Gland Carcinoma
Primary: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) — 9; 7 Participants — p=<0.10
Phase 2 N=42 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Thyroid Cancer
Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants
Phase 2 N=50 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer
Thyroid Cancer
Primary: Median Progression Free Survival — 12.5 months
Phase 2 N=34 Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer
Thyroid Cancer · Differentiated Thyroid Carcinoma
Primary: The Rate of Successful Thyroid Ablation as Defined by Negative Recombinant Human Thyrotropin (rhTSH) Stimulated Radioiodine Whole Body Scan (RAI WBS) at 1 Year. — 10; 10…
Phase 2 N=127 Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
Refractory Differentiated Thyroid Gland Carcinoma · Refractory Thyroid Gland Follicular Carcinoma · Refractory Thyroid Gland Hurthle Cell Carcinoma
Primary: Dose Limiting Toxicity — 0; 1; 2 Participants
Phase 3 N=417 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer
Thyroid Neoplasms
Primary: Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation — 329; 175 Days — p=<0.0001
Phase 2 N=35 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Overall Response Rate — 11 Participants
N/A N=142 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis
Differentiated Thyroid Cancer · Osteoporosis
Primary: Percent Change of Bone Mineral Density in Lumbar and Hip — 3.0; 3.2; 3.8; 5.1 percentage change
Phase 2 N=13 A Phase II Trial of Valproic Acid in Patients With Advanced Thyroid Cancers of Follicular Cell Origin
Thyroid Neoplasm
Primary: RAI (Radioactive Iodine) Uptake and Tg (Thyroglobulin) Level Compared Pre and Post- Valproic Treatment — 6; 1; 1; 0 Participants
Phase 2 N=12 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
Recurrent Thyroid Cancer · Stage IVA Follicular Thyroid Cancer · Stage IVA Papillary Thyroid Cancer
Primary: Restoration of Radioiodine Uptake in Metastatic Lesions as Demonstrated by Diagnostic Whole-body Scanning After Decitabine Administration — 0 participants
Phase 2 N=59 Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
Metastatic Differentiated Thyroid Cancer · Metastatic Poorly Differentiated Thyroid Cancer · Metastatic Anaplastic Thyroid Cancer
Primary: To Determine the Efficacy (Best Response) of BAY 43-9006 (Objective Response Rate and Stable Disease) in Patients With Metastatic Thyroid Carcinoma. — 0; 16; 22; 1…
N/A N=126 The Effect of Surgeon Emotional Support on Treatment Choice for Low-risk Thyroid Cancer
Thyroid Cancer · Thyroid Nodule · Benign Thyroid Nodule
Primary: Treatment Choice — 54; 51; 6; 7 Participants — p=0.720
Phase 2 N=22 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants
Phase 2 N=3 Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Primary: Overall Survival Rate — 0 percentage of participants alive
Phase 2 N=52 Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
Thyroid Neoplasms
Primary: Percentage of Participants With Objective Response (OR) — 34.6 percentage of participants
Phase 2 N=152 Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
Recurrent Thyroid Gland Carcinoma · Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 · Stage III Thyroid Gland Medullary Carcinoma AJCC v7
Primary: Overall Response Rate (in Cohorts 1-3) — 49; 14; 0 percentage of participants
Phase 2 N=27 Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy
Head and Neck Cancer
Primary: Objective Tumor Response Rate at 3, 6, and 12 Months — 0; 0; 12; 13 participants
Phase 2 N=3 A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Anaplastic Thyroid Cancer · Thyroid Cancer · Differentiated Thyroid Cancer
Primary: Maximum Tolerated Dose (MTD) [Phase I Dose Escalation] — 5 mg
Phase 2 N=25 Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Poorly Differentiated Thyroid Gland Carcinoma · Recurrent Thyroid Gland Carcinoma · Stage I Thyroid Gland Follicular Carcinoma
Primary: Objective Response Rate, Defined as the Proportion of Patients Who Have Had a PR or CR as Assessed by the RECIST Version (v)1.1 — 10 Participants